Laura Christine Cappelli, M.D., M.H.S., M.S.

Headshot of Laura Christine Cappelli
  • Associate Professor of Medicine


Internal Medicine, Rheumatology

Research Interests

Arthritis; Rheumatology; Inflammation


Johns Hopkins Bayview Medical Center

5200 Eastern Ave.
Mason F. Lord Building, Center Tower Suite 4100
Baltimore, MD 21224 map


Dr. Laura Cappelli is an Assistant Professor of Medicine and Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include rheumatology and adverse effects from cancer immunotherapy.

Dr. Cappelli earned her M.D. from Johns Hopkins. She completed her residency in internal medicine and performed a fellowship in rheumatology at the Johns Hopkins Hospital. She has a MHS in Clinical Investigation from the Johns Hopkins Bloomberg School of Public Health.

Dr. Cappelli's research focuses on different forms inflammatory arthritis. Specifically, she studies a new type of inflammatory arthritis due to immunotherapy treatments for cancer and rheumatoid arthritis. more


  • Associate Professor of Medicine
  • Associate Professor of Oncology

Departments / Divisions



  • MD; Johns Hopkins University School of Medicine (2010)


  • Internal Medicine; Johns Hopkins University School of Medicine (2013)


  • Rheumatology; Johns Hopkins University School of Medicine (2016)

Board Certifications

  • American Board of Internal Medicine (Internal Medicine) (2013)
  • American Board of Internal Medicine (Rheumatology) (2016)

Research & Publications

Research Summary

Dr. Cappelli has started a research program to evaluate the rheumatologic adverse effects of cancer immunotherapy.  Immune checkpoint inhibitors, work to boost patients’ own immune systems to fight their cancer, leading to great advances in treatment. However, they can also lead to adverse events as a result of their mechanism of action.  Rheumatologists are seeing patients with inflammatory arthritis, immune-mediated dry mouth and dry eyes, myositis, vasculitis and other adverse events due to cancer immunotherapy. Dr. Cappelli is investigating several different aspects of these adverse events including the clinical characteristics, epidemiology, impact on patients, and the biologic mechanisms. Her work involves collaborations with oncologists and laboratory investigators in rheumatology and oncology. Through this research, guidelines for evaluation and management of adverse events can be developed and those at greatest risk for adverse events may be identified.  

Dr. Cappelli also has a research interest in rheumatoid arthritis. She focuses on the use of autoantibodies as biomarkers and on patients with seronegative rheumatoid arthritis. 

Selected Publications

Cappelli LC, Bingham CO 3rd. Spectrum and impact of checkpoint inhibitor-induced irAEs. Nat Rev Rheumatol. 2021 Feb;17(2):69-70. doi: 10.1038/s41584-020-00546-2. PubMed PMID: 33235330

Braaten TJ, Brahmer JR, Forde PM, Le D, Lipson EJ, Naidoo J, Schollenberger M, Zheng L, Bingham CO, Shah AA, Cappelli LC. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 2020 Mar;79(3):332-338. doi: 10.1136/annrheumdis-2019-216109. Epub 2019 Sep 20. PubMed PMID: 31540935; PubMed Central PMCID: PMC7031780

Naidoo J, Zhang J, Lipson EJ, Forde PM, Suresh K, Moseley KF, Mehta S, Kwatra SG, Parian AM, Kim AK, Probasco JC, Rouf R, Thorne JE, Shanbhag S, Riemer J, Shah AA, Pardoll DM, Bingham CO, Brahmer JR, Cappelli LC. A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events. J Natl Compr Canc Netw. 2019 Jun 1;17(6):712-720. doi: 10.6004/jnccn.2018.7268. PubMed PMID: 31200355

Cappelli LC, Konig MF, Gelber AC, Bingham CO 3rd, Darrah E. Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis. Arthritis Res Ther. 2018 Mar 23;20(1):59. doi: 10.1186/s13075-018-1533-z. PubMed PMID: 29566742; PubMed Central PMCID: PMC5865363

Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, Lipson EJ, Bleich KB, Shah AA, Naidoo J, Brahmer JR, Le D, Bingham CO 3rd. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017 Jan;76(1):43-50. doi: 10.1136/annrheumdis-2016-209595. Epub 2016 Jun 15. PubMed PMID: 27307501; PubMed Central PMCID: PMC5333990

Contact for Research Inquiries

Hopkins Bayview Circle, Suite 1B1
Baltimore, MD 21224 map

Activities & Honors


  • American College of Rheumatology

Videos & Media

Recent News Articles and Media Coverage

5 Tips for Getting the Most Out of Your next Rheumatoid Arthritis Appointment, (3/10/2021)

What to Ask a Doctor if You Get a Rheumatoid Arthritis Diagnosis, (9/25/2020)

Ultrasound Provides Insights into Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis, The Rheumatologist (10/12/2020)

Arthritis Emerges After Cancer Immunotherapy, Medpage Today, (June 17, 2016)

Checkpoint Inhibitors Linked to Inflammatory Arthritis, Medscape (June 29, 2016)

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

Is this you? Edit Profile
back to top button